Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
08:30am, Wednesday, 07'th Feb 2024
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the Oppenheimer 34th Annual Healthcare Life Scienc
Why Earnings Season Could Be Great for Ascendis Pharma (ASND)
09:51am, Tuesday, 06'th Feb 2024
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
04:15pm, Wednesday, 31'st Jan 2024
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, Fe
Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript
08:22pm, Tuesday, 07'th Nov 2023
Ascendis Pharma A/S (ASND) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Timothy Lee - Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
08:30am, Tuesday, 31'st Oct 2023
• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-Novem
Ascendis Pharma A/S (ASND) Loses -8.26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:23am, Thursday, 26'th Oct 2023
The heavy selling pressure might have exhausted for Ascendis Pharma A/S (ASND) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Ascendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?
09:01am, Friday, 15'th Sep 2023
Ascendis Pharma A/S (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript
07:43pm, Tuesday, 05'th Sep 2023
Ascendis Pharma A/S (ASND) Q2 2023 Earnings Conference Call September 5, 2023 4:30 PM ET Company Participants Tim Lee - Senior Director, Investor Relations Jan Mikkelsen - President and Chief Executiv
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
08:30am, Tuesday, 15'th Aug 2023
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday,
How Much Upside is Left in Ascendis Pharma A/S (ASND)? Wall Street Analysts Think 47.35%
11:30am, Thursday, 10'th Aug 2023
The mean of analysts' price targets for Ascendis Pharma A/S (ASND) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
08:30am, Wednesday, 07'th Jun 2023
COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice Presi
Ascendis Pharma shares pop after FDA rejects hormone therapy application but not the underlying clinical data
01:57pm, Monday, 01'st May 2023
The US Food and Drug Administration (FDA) did not grant its approval to Ascendis Pharma's experimental hormone disorder therapy, but the company's stock has soared Monday nonetheless. The therapy, c
Why Shares of Ascendis Pharma Are Climbing Monday
11:45am, Monday, 01'st May 2023
Ascendis has seen a big uptake in sales for its human growth hormone therapy. The company said it plans to request a meeting with the FDA regarding hyperthyroidism therapy TransCon PTH.
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript
10:34pm, Thursday, 27'th Apr 2023
Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript.
These Are the Top 10 Holdings of Avoro Capital Advisors
10:54pm, Monday, 17'th Apr 2023
Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.
